Status:
COMPLETED
A Study of Continuous Heart Rate Monitoring in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
21-65 years
Phase:
NA
Brief Summary
The main purpose of this study in healthy participants is to find out whether a heart rate monitor will accurately pick up changes in heart rate caused by 2 different medications (pseudoephedrine and ...
Eligibility Criteria
Inclusion
- Are overtly healthy males or females
- Have a body mass index (BMI) of 18.0 to 35 kilograms/square meter (kg/m2), inclusive at screening
- Have blood pressure, pulse rate, blood and urine laboratory test results that are acceptable for the study
- Have given written informed consent approved by Lilly and the ethical review board governing the site
Exclusion
- Have or used to have health problems that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
- Have history of sensitive skin or chronic skin conditions, like eczema
- Regularly use known drugs of abuse
- Are women who are pregnant or lactating
- Have known allergies to medications used in the study
Key Trial Info
Start Date :
January 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 25 2021
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04682184
Start Date
January 27 2021
End Date
March 25 2021
Last Update
April 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lilly Centre for Clinical Pharmacology
Singapore, Singapore, 138623